Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $81.81, marking a +1.98% move from the previous day.

Zacks Equity Research

Moleculin Surges on Manufacturing Deal for Coronavirus Therapy

by Zacks Equity Research

Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.

Zacks Equity Research

Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Zacks Equity Research

Stock Market News for Jul 16, 2020

by Zacks Equity Research

Benchmarks edged up on Wednesday as investors cheered promising data for a potential COVID-19 vaccine and few better-than-expected quarterly earnings reports.

Sweta Killa headshot

Travel & Leisure ETFs Jump on Vaccine Optimism

by Sweta Killa

Investors rushed to the beaten-down sectors, including cruise lines, airlines, hotel and casino operators, and travel and entertainment-booking companies.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi

Nilanjan Banerjee headshot

Coronavirus Vaccine Hopes Buoy Market: 4 Stocks to Tap the Rally

by Nilanjan Banerjee

With the doses of good news aiding the stock market rally, it will be wise for the investors to invest in growth stocks.

Zacks Equity Research

Moderna (MRNA) in Focus: Stock Moves 6.9% Higher

by Zacks Equity Research

Moderna (MRNA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Sanghamitra Saha headshot

Vaccine Hopes Boost These Sectors & ETFs

by Sanghamitra Saha

Vaccine hopes and some upbeat banking earnings have boosted the risk-on sentiments in Wall Street.

Sweta Jaiswal, FRM headshot

Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

by Sweta Jaiswal, FRM

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.